--- title: 'Life Sciences Daily Summary: What Happened on November 4, 2026' headline: Servier’s sevasemten misses Phase 3 goal in Becker muscular dystrophy description: The FDA set a May 2027 review date for uniQure’s Huntington’s gene therapy. Warp Sciences raised $215 million, and Processa acquired Vidya. url: https://thebench.bio/news/summaries/2026-11-04 topic: all date: '2026-11-04' covers: - '2026-11-04' date_published: '2026-11-04T12:03:36Z' date_modified: '2026-11-04T12:03:36Z' tags: - Funding - Regulatory - Software sources: 4 publisher: TheBench.Bio --- # Life Sciences Daily Summary: What Happened on November 4, 2026 **Servier’s sevasemten misses Phase 3 goal in Becker muscular dystrophy** The FDA set a May 2027 review date for uniQure’s Huntington’s gene therapy. Warp Sciences raised $215 million, and Processa acquired Vidya. ## Today in brief Servier’s sevasemten failed to improve muscle function on the primary measure in a Phase 3 Becker muscular dystrophy trial. [1] The FDA granted Priority Review to uniQure’s Huntington’s gene-therapy application, with a target decision date of May 1, 2027. [2] Warp Sciences emerged from stealth with $215 million to build a US medicinal-chemistry service combining chemists, AI and robotics. [3] Processa acquired Vidya Therapeutics and has $200 million in financing for a pipeline led by Vidya’s BTK inhibitor VT-7208. [4] ## Servier’s sevasemten misses Phase 3 endpoint In the 18-month GRAND CANYON Phase 3 trial, sevasemten did not improve the primary NSAA measure of muscle function versus placebo in 175 adults with Becker muscular dystrophy. [1] The trial also missed its secondary endpoints. [1] Servier said the drug had a favorable safety and tolerability profile and that it is reviewing the broader results. [1] In an earlier Phase 2 study, sevasemten reduced creatine kinase, but the difference in NSAA scores between treatment and placebo was not statistically significant. [1] Servier paid $1.55 billion upfront for Edgewise Therapeutics’ muscular dystrophy business, with up to $1.1 billion in potential milestone payments. [1] ## FDA grants uniQure’s Huntington’s therapy Priority Review The FDA accepted uniQure’s application for ifezuntirgene inilparvovec through the accelerated approval pathway and granted it Priority Review. [2] The agency set May 1, 2027, as its target action date and provisionally indicated that it plans to convene an advisory committee. [2] The application draws on 36-month results from a Phase I/II study compared with an external group in the Enroll-HD natural-history registry. [2] UniQure and the FDA agreed on a randomized confirmatory trial of about 200 patients, with Total Functional Capacity at 36 months as the primary endpoint. Screening is scheduled to begin in the United States before the end of 2026. [2] ## Warp Sciences raises $215 million for US chemistry operation Warp Sciences emerged from stealth with $215 million in financing led by Lightspeed, at an $865 million valuation, to establish a US medicinal-chemistry contract research business. [3] The company plans to pair experienced chemists with AI and robots, and says it will charge for each compound delivered rather than for chemist time. [3] Warp’s approach starts with chemists, using their work as data to automate more of the process over time. [3] ## Processa buys Vidya and backs pipeline with $200 million Processa acquired Vidya Therapeutics, and Sheila Gujrathi became executive chair of the combined company. [4] The combined company has $200 million in PIPE financing and is developing Vidya’s BTK inhibitor VT-7208 for food allergies, chronic spontaneous urticaria and relapsing multiple sclerosis. [4] ## The day in numbers - **175**: Adults enrolled in Servier’s Phase 3 GRAND CANYON trial. [1] - **May 1, 2027**: FDA target action date for uniQure’s Huntington’s gene-therapy application. [2] - **$215 million**: Warp Sciences’ financing to establish a US medicinal-chemistry operation. [3] - **$200 million**: PIPE financing for Processa and Vidya’s combined company. [4] ## Sources 1. [Servier’s $1.55B Edgewise acquisition backfires after Phase 3 setback](), European Biotechnology, 2026-11-04 2. [FDA to review uniQure’s BLA for Huntington’s gene therapy](), Pharmaceutical Technology, 2026-11-04 3. [Weekly Tech+Bio #89: Can Robots Bring Drug-Discovery Chemistry Back to the US?](), Weekly Tech+Bio, 2026-11-04 4. [With Vidya acquisition, Gujrathi takes chair role at Processa](), BioCentury, 2026-11-04 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: